SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.
Jamie Chaft, Jay M Lee, Suresh Senan...
https://pubmed.ncbi.nlm.nih.gov/42823821/Actively Recruiting
Led by Eli Lilly and Company · Updated on 2026-11-04
700
Participants Needed
368
Research Sites
143 weeks
Total Duration
Researchers are evaluating whether olomorasib combined with immunotherapy is more effective than standard immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer NSCLC. The study has two parts Part A focuses on participants with resected NSCLC treated with pembrolizumab, and Part B includes participants with unresectable NSCLC treated with durvalumab. This Phase 3 study aims to assess disease control and survival outcomes over several years. Participants will be randomly assigned to receive either olomorasib or a placebo, both given orally, combined with intravenous pembrolizumab or durvalumab depending on the study part. Treatment with the combination lasts for up to 1 year, followed by olomorasib or placebo alone for up to 3 years. The study involves parallel groups comparing these combinations in participants with either resected or unresectable disease. During the study, participants will have regular assessments including disease monitoring for progression or recurrence, quality of life questionnaires, and evaluations of lung cancer symptoms. Researchers will track outcomes such as disease-free survival in Part A and progression-free survival in Part B, along with overall survival and symptom changes. The total participation may last about 3 years, with ongoing follow-up to monitor safety and treatment effects.
CONDITIONS
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Eli Lilly and Company
Lead Sponsor
AstraZeneca
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Olomorasib + immunotherapy | Placebo + immunotherapy |
|---|---|---|
| What it is | Oral KRAS G12C inhibitor (olomorasib) added to standard immunotherapy (pembrolizumab or durvalumab) | Oral placebo with the same immunotherapy backbone |
| Role in trial | Investigational treatment arm being evaluated for added benefit | Placebo‑controlled comparator arm |
| Primary use | Evaluate whether adding olomorasib improves disease‑free or progression‑free survival alongside immunotherapy | Serve as control to assess outcomes with immunotherapy alone |
| How it is given or performed | Participants take oral olomorasib plus intravenous pembrolizumab or durvalumab | Participants take oral placebo plus intravenous pembrolizumab or durvalumab |
| Evidence status | Efficacy under evaluation; no results posted yet | Efficacy of immunotherapy alone is established in similar NSCLC settings |
| Important risks | Safety data are not yet available for this combination | Immunotherapy safety profile is known (such as potential immune‑related side effects) |
| Important limitations | Unknown whether adding KRAS G12C inhibitor increases toxicity or improves long‑term outcomes | Control arm may not reflect future treatments if KRAS G12C inhibitors become standard |
| Patient impact | Not yet established until trial outcomes are available | Immunotherapy can improve survival and quality of life in stage III NSCLC patients |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 years
Participants receive either olomorasib or placebo orally combined with intravenous pembrolizumab or durvalumab depending on their study part. Combination treatment lasts up to 1 year followed by olomorasib or placebo alone for up to 3 years.
Regular visits during treatment period
Duration - Up to 5 years
Participants are monitored for disease progression, survival, quality of life, and symptoms through questionnaires and clinical assessments.
Periodic visits for assessments
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Jamie Chaft, Jay M Lee, Suresh Senan...
https://pubmed.ncbi.nlm.nih.gov/42823821/Eli Lilly and Company
Lead Sponsor
AstraZeneca
Collaborating Sponsor